Can a new medication improve walking without levodopa?

Trial Spotlight — Phase 2 / Phase 3 Can a new medication improve walking without levodopa? Most Parkinson's medications work by increasing dopamine signaling in the brain. VG081821AC takes a different approach: it blocks a protein called the adenosine A2A receptor, which normally puts a brake on movement-related brain circuits. By releasing that brake, the drug aims to improve movement, walking, and daily activity without needing levodopa at all. This is a meaningful distinction. A treatment that works independently of levodopa could be particularly valuable for people in the early stages of Parkinson's who have not yet started levodopa, preserving more options for later in the disease course. The trial is enrolling 152 adults aged 18 to 80 with early to mid-stage Parkinson's diagnosed within about 7 years, at clinical stage 1 to 3, who have not taken levodopa in the four weeks before joining. Participants visit the clinic 8 times over 12 weeks for symptom and safety checks. See full listing --- Also recruiting Probiotics reduce acting out dreams Reduce hallucinations without worsening movement